Multiple Sclerosis: Effect of Gamma Linolenate Administration upon Membranes and the Need for Extended Clinical Trials of Unsaturated Fatty Acids
- 1 January 1983
- journal article
- research article
- Published by S. Karger AG in European Neurology
- Vol. 22 (1), 78-83
- https://doi.org/10.1159/000115540
Abstract
Electrophoretic mobility studies of red blood cells from subjects with multiple sclerosis indicate that treatment with unsaturated fatty acids must continue for at least 2 years before normal reactivity is restored by currently available tests. If this applies to myelin also, then clinical trials aimed at treating the recognized multiple sclerosis subject by polyunsaturated fatty acids really begin after 2 years, and this should be recognized when a trial program is drawn up.Keywords
This publication has 6 references indexed in Scilit:
- Linoleic acid in multiple sclerosis: Failure to show any therapeutic benefitActa Neurologica Scandinavica, 2009
- Levels of linoleate and arachidonate in red blood cells of healthy individuals and patients with multiple sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 1980
- Further Observations with the Erythrocyte-Unsaturated Fatty Acid TestEuropean Neurology, 1980
- Erythrocyte unsaturated fatty acid test (E-UFA test): A biological test to detect optic neuritis as initial feature of multiple sclerosisZeitschrift für Neurologie, 1979
- Effect of Prolonged Ingestion of γ-Linolenate by MS PatientsEuropean Neurology, 1978
- Erythrocyte-UFA (Eufa) mobility test for multiple sclerosis: Implications for pathogenesis and handling of the diseaseZeitschrift für Neurologie, 1977